SAN DIEGO, May 10, 2004 (PRIMEZONE) -- Cell Bio-Systems, Inc. (Pink Sheets:CBSI), a biotechnology company seeking to manufacture and distribute patented, disposable technologies for cosmetic surgery, biopsy, orthopedic surgery and other living tissue procedures, announced today that it has approved its first three injection tip configurations for the fat re-injection market.
The new tip styles are a combination of designs currently used in the reusable market, along with design modifications based on feedback received from leading doctors aligned with Cell Bio-Systems. They will serve as the company's core configurations introduced to the fat re-injection market and later may be adapted for other living tissue markets.
"Our Living Tissue Management System is designed for quality and performance," said Marc Pilkington, CBSI president and CEO. "Our technology integrates a smooth tube surface technology and precision engineered tip configurations combined with our patented SuperLuer connection system. Every step in the process has a coordinated purpose."
Cell Bio-Systems recently announced the completion of its first set of production tools for the manufacture of the company's flagship instrument, the SuperLuer, a patented connection system and the centerpiece component for the company's bio-device kits utilized in procedures ranging from liposuction and fat re-injections to gene therapy technologies and stem cell research.
About Cell Bio-Systems
Based in San Diego, California, Cell Bio-Systems is the exclusive licensee of two patented syringe connection products that it plans to adapt as disposable devices for liposuction and other Living Tissue Management(tm) procedures. The company is developing an affordable, disposable product line that will fill this void in the cosmetic surgery and living tissue marketplace. The company's patented, groundbreaking technology will increase patient safety and enhance procedural outcomes. Most notably, Cell Bio-Systems devices can be adapted for a variety of procedures, ranging from fat transfers to biopsies to stem cell research. The company ultimately will develop a complete living tissue management system. For more information, please visit www.cellbiosystems.com.
Legal Notice Regarding Forward-Looking Statements: "Forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 may be included in this news release. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. CBSI disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to risks associated with changes in general economic and business conditions (including in the information technology and financial information industry), actions of our competitors, the extent to which we are able to develop new services and markets for our services, the time and expense involved in such development activities, the level of demand and market acceptance of our services, and changes in our business strategies.